touchFEATURE

Recognizing mycosis fungoides, a heterogeneous and challenging cutaneous T-cell lymphoma

Watch Time: 3 mins

to access this content

This activity has been sponsored by Helsinn Healthcare SA and Recordati Rare Diseases. Helsinn Healthcare SA provided financial support and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

This content is for healthcare professionals in the following counties only: Argentina, Austria, Belgium, Colombia, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, and Switzerland.

Please confirm that you are a healthcare professional in one of those countries.

Decline

This activity has been sponsored by Helsinn Healthcare SA and Recordati Rare Diseases. Helsinn Healthcare SA provided financial support and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Melanoma View Time: 3 mins

touchFEATURE Recognizing mycosis fungoides, a heterogeneous and challenging cutaneous T-cell lymphoma

Watch this activity to learn more about mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and a new MF-CTCL online resource.

Visit MF-Talks for more information.

 
Videos
MF-CTCL: Mechanism of disease

MF is a cutaneous T-cell lymphoma characterised by clonal proliferation of mutated, skin-homing T-cells

Video content supplied by Helsinn Healthcare SA.

1/3 Next Chapter
 
Challenges in diagnosing MF-CTCL

Diagnosing MF-CTCL in clinical practice is difficult and may take years because early MF lesions can appear to be similar to benign dermatosis

Video content supplied by Helsinn Healthcare SA.

2/3 Next Chapter
 
MF-Talks: a new resource for MF-CTCL

MF-Talks is a website that aims to shed light on mycosis fungoides. It provides current and emerging information on this under-recognized cutaneous lymphoma, and includes sections dedicated to healthcare professionals.

Video content supplied by Helsinn Healthcare SA.

3/3 Leave Feedback
Leave Feedback
Learning Objectives & Overview
Overview

Mycosis fungoides (MF) is characterised by the proliferation of epidermic, cerebriform T-cells. This condition is distinguished by some key pathological and symptomatic features, that can be mistaken with signs of benign dermatosis. Thus, diagnosis is difficult to make and may take years.

MF-Talks is an online resource that aims to shed light on mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL). It provides up-to-date information, lists of expert centres, patient associations and scientific societies dedicated to the disease, as well as news about upcoming congresses and events.

Visit MF-Talks to learn more.

mf talks logo

Learning Objectives

After watching this activity, participants should be better able to:

  • Understand the role of T-cells in MF-CTCL pathology
  • Recognize that clinical signs and symptoms of MF-CTCL can be mistaken for benign dermatosis
  • Appreciate the importance of correlating clinical and pathological findings in MF-CTCL diagnosis
  • Understand that a new resource, MF-Talks, can provide further information on MF-CTCL
References
References
  1. Larocca C et al. Hematol Oncol Clin North Am. 2019;33(1):103-120.
  2. Jawed S et al. JAAD. 2014 Feb;70(2):205.e1-16; quiz 221-2.
  3. Wilcox RA. Am J Hematol. 2017;92(10):1085-1102.
  4. Vaidya T, Badri T. Mycosis Fungoides Stat Pearls. https://www.ncbi.nlm.nih.gov/books/NBK519572/ (accessed August 2021)
  5. Denis D et al. Cancer Manag Res. 2019;11:2241-51.
  6. Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas [version 1; peer review: 2 approved]. F1000Research 2016; 5(F1000 Faculty Rev):1882. Available at: https://f1000research.com/articles/5-1882 (accessed August 2021)
  7. García-Díaz N et al. Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers 2021;13:1931. Available at: www.mdpi.com/2072-6694/13/8/1931 (accessed August 2021)
  8. Anorim GM et al. An Bras Dermatol. 2018;93:546–52
  9. Geskin L et al. Dermatol Ther (Heidelb). 2021;11:1085-1106.
  10. Trautinger F et al. Eur J Cancer. 2017;77:57–74
  11. Ahn CS et al. Am J Dermatopathol. 2014;36:933–48
  12. MF-Talks. 2021. Available at www.mf-talks.com (accessed March 2022)
Feedback Close
Feedback

Please provide feedback for this touchFEATURE on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72